Katherine Bell-McGuinn

Katherine Bell-McGuinn is a seasoned professional in clinical development and oncology, currently serving as the Senior Vice President of Clinical Development at Ottimo Pharma since February 2025. Prior to this role, Katherine was the Chief Medical Officer at 858 Therapeutics from November 2023 to February 2025 and held various leadership positions at AbbVie, including Vice President and Head of Oncology Early Development, from March 2020 to October 2023. Katherine's career also includes significant contributions at Eli Lilly and Company as a Medical Fellow and Senior Medical Advisor, and experience as an Assistant Attending Physician at Memorial Sloan Kettering Cancer Center. Katherine's educational background includes an M.D./Ph.D. in Pharmacology from The Johns Hopkins University School of Medicine, a residency in Internal Medicine at The Johns Hopkins Hospital, and degrees in Chemistry and Mathematics from Texas Lutheran University.